Kevin Golden, MD
Infectious Disease · Fort Worth, TXNPI 1801274477
Payments from drug & device makers
Across 424 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Insmed, Inc.$911
- Gilead$723
- Merck$531
- Shionogi Inc$489
- AbbVie$463
- plus $3K from 25 others
What the payments were for
- Food & beverage$8,43797%
- Education$2633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 144 | $3,030 |
| Insmed, Inc. | 39 | $911 |
| Gilead | 33 | $723 |
| Merck | 30 | $531 |
| Shionogi Inc | 27 | $489 |
| AbbVie | 25 | $463 |
| Paratek Pharmaceuticals, Inc. | 29 | $442 |
| Astellas Pharma US Inc | 14 | $378 |
| EMD Serono, Inc. | 14 | $245 |
| Theratechnologies Inc. | 12 | $236 |
| Medtronic | 1 | $164 |
| Cumberland Pharmaceuticals, Inc. | 8 | $112 |
| CSL Behring | 4 | $106 |
| La Jolla Pharmaceutical Company | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Melinta Therapeutics, LLC | 4 | $82 |
| Napo Pharmaceuticals Inc | 4 | $80 |
| Ferring Pharmaceuticals Inc. | 3 | $64 |
| Grifols USA, LLC | 3 | $62 |
| Mayne Pharma Commercial LLC | 3 | $60 |
| Octapharma USA, Inc. | 3 | $56 |
| Aimmune Therapeutics, Inc. | 3 | $55 |
| Johnson & Johnson | 2 | $52 |
| Pfizer | 2 | $39 |
| Amgen | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Invivyd Inc | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Hospira, Inc. | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$164
How this compares
$8,700 in reported general payments places this provider in the 80th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 117 | $63,218 |
| Meropenem | 89 | $21,449 |
| ErtapenemErtapenem Sodium | 39 | $17,183 |
| MicafunginMicafungin Sodium | 28 | $15,194 |
| Caspofungin Acetate | 26 | $14,859 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $10,753 |
| Fosfomycin Tromethamine | 44 | $9,126 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 31 | $8,568 |
| Cefepime Hcl | 60 | $7,913 |
| Rifabutin | 15 | $6,035 |
| Vancomycin Hcl | 27 | $4,586 |
| CeftriaxoneCeftriaxone Sodium | 58 | $3,288 |
| Cefazolin Sodium | 33 | $2,290 |
| Ceftazidime | 40 | $2,267 |
| Doxycycline Hyclate | 83 | $1,800 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Fort Worth
- Cheryl McDonaldFort Worth$3.1M
- Cedric SpakFort Worth$427K
- Catherine ColquittFort Worth$142K
- Gene VoskuhlSherman$69.5M
- Mezgebe BerheDallas$11M
- Eleftherios MylonakisHouston$6.4M
- Mamta JainDallas$3.7M
- Ogechika AlozieEl Paso$2.5M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.